Outcomes of Patients Undergoing Third Hematopoietic Cell Transplantation for Hematologic Malignancies

Overview

Journal Ann Hematol

Specialty Hematology

Date 2024 Jul 13

PMID 39003390

Authors

Emily R Cox

Corinne Summers

Filippo Milano

Ann Dahlberg

Marie Bleakley

Brenda M Sandmaier

Monica S Thakar

Affiliations

Soon will be listed here.

Abstract

With advancements in novel therapeutics, it is unclear whether third hematopoietic cell transplantation (HCT3) has a place in the treatment of recurrent hematopoietic malignancies. We evaluated patients with hematologic malignancies who underwent HCT3 between 2000-2020. Nine patients, with a median age of 18 (9-68) years at HCT3 with acute myelogenous leukemia (n = 5), acute lymphoblastic leukemia (n = 2), myelodysplastic syndrome (n = 1), or undifferentiated acute leukemia (n = 1), were identified. The median time between first HCT and HCT3 was 3.9 (0.7-13.6) years. Indication for HCT3 was relapse (n = 8) or graft failure (n = 1) after second HCT. At HCT3, seven of nine patients were in complete remission by flow cytometry. All experienced robust donor engraftment by one month after HCT3 (≥ 90% CD3) while one died at day + 24 of multi-organ failure and was not evaluable for chimerism. In total, eight patients died from relapse (n = 4), non-relapse, (n = 3) or unknown (n = 1) causes at a median of 0.6 (range, 0.1 - 9.9) years after HCT3. After HCT3, estimated overall survival at 6 months, 1 year, and 5 years was 88%, 63%, and 22%, respectively. In this highly selected group, HCT3 provided a treatment option although long-term survival was still dismal.

References

Bar M, Sandmaier B, Inamoto Y, Bruno B, Hari P, Chauncey T . Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant. 2013; 19(6):949-57. PMC: 3846289. DOI: 10.1016/j.bbmt.2013.03.001. View

Kekre N, Kim H, Thanarajasingam G, Armand P, Antin J, Cutler C . Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015; 100(9):1222-7. PMC: 4800679. DOI: 10.3324/haematol.2015.129650. View

Chang Y, Huang X . Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?. Blood Rev. 2012; 27(1):55-62. DOI: 10.1016/j.blre.2012.11.002. View

Liberio N, Robinson H, Nugent M, Simpson P, Margolis D, Malarkannan S . Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019; 66(11):e27950. PMC: 6754268. DOI: 10.1002/pbc.27950. View

Ciurea S, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G . Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2021; 36(1):155-164. PMC: 8727305. DOI: 10.1038/s41375-021-01349-4. View

Smith M, Zakrzewski J, James S, Sadelain M . Posttransplant chimeric antigen receptor therapy. Blood. 2018; 131(10):1045-1052. PMC: 5865610. DOI: 10.1182/blood-2017-08-752121. View

Zhang C, Wang X, Zhang R, Liu F, Wang Y, Yan Z . Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant. Leukemia. 2020; 35(6):1563-1570. PMC: 8179843. DOI: 10.1038/s41375-020-01056-6. View

Chen Y, McCarthy P, Hahn T, Holstein S, Ueda M, Kroger N . Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplant. 2018; 54(4):497-507. DOI: 10.1038/s41409-018-0269-3. View

Dahlberg A, Leisenring W, Bleakley M, Meshinchi S, Baker K, Summers C . Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children. Bone Marrow Transplant. 2019; 54(8):1337-1345. PMC: 6646113. DOI: 10.1038/s41409-019-0438-z. View

10.

Eapen M, Giralt S, Horowitz M, Klein J, Wagner J, Zhang M . Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant. 2004; 34(8):721-7. DOI: 10.1038/sj.bmt.1704645. View

11.

Yaniv I, Krauss A, Beohou E, Dalissier A, Corbacioglu S, Zecca M . Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study. Biol Blood Marrow Transplant. 2018; 24(8):1629-1642. DOI: 10.1016/j.bbmt.2018.03.002. View

12.

Kobayashi S, Kanda Y, Konuma T, Inamoto Y, Matsumoto K, Uchida N . Outcomes of third allogeneic hematopoietic stem cell transplantation in relapsed/refractory acute leukemia after a second transplantation. Bone Marrow Transplant. 2021; 57(1):43-50. DOI: 10.1038/s41409-021-01485-6. View

13.

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V . Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009; 15(12):1628-33. PMC: 2861656. DOI: 10.1016/j.bbmt.2009.07.004. View

14.

Gyurkocza B, Sandmaier B . Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014; 124(3):344-53. PMC: 4102707. DOI: 10.1182/blood-2014-02-514778. View

15.

Filipovich A, Weisdorf D, Pavletic S, Socie G, Wingard J, Lee S . National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12):945-56. DOI: 10.1016/j.bbmt.2005.09.004. View

16.

Przepiorka D, Weisdorf D, MARTIN P, Klingemann H, Beatty P, Hows J . 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15(6):825-8. View

17.

Sorror M, Maris M, Storb R, Baron F, Sandmaier B, Maloney D . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8):2912-9. PMC: 1895304. DOI: 10.1182/blood-2005-05-2004. View

18.

Sorror M, Storer B, Sandmaier B, Maloney D, Chauncey T, Langston A . Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008; 112(9):1992-2001. DOI: 10.1002/cncr.23375. View

19.

Christopeit M, Kuss O, Finke J, Bacher U, Beelen D, Bornhauser M . Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. J Clin Oncol. 2013; 31(26):3259-71. DOI: 10.1200/JCO.2012.44.7961. View

20.

Ruutu T, de Wreede L, van Biezen A, Brand R, Mohty M, Dreger P . Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT. Bone Marrow Transplant. 2015; 50(12):1542-50. DOI: 10.1038/bmt.2015.186. View